FDA Names Oncology Expert Pazdur as New Drug Regulator

November 12, 2025 Victoria Sterling Business
News Context
At a glance
  • On May 9,2024,the Food and Drug Governance (FDA) announced the appointment of Richard Pazdur as the Principal Deputy Commissioner for Drug Evaluation and Research (PDCR).
  • This appointment is particularly noteworthy given the increasing complexity of drug development and the FDA's ongoing efforts to balance the need for faster access to innovative treatments with...
  • Richard Pazdur is a highly respected figure in the pharmaceutical and regulatory communities.
Original source: washingtonpost.com

“`html





<a href="https://www.newsdirectory3.com/car-t-therapy-fda-rems-removal/" title="CAR T Therapy: ... REMS Removal">Richard Pazdur</a> Appointed as FDA’s Chief Drug Regulator


Richard Pazdur Named FDA’s Principal Deputy Commissioner for Drug Evaluation and Research

Table of Contents

What Happened?

On May 9,2024,the Food and Drug Governance (FDA) announced the appointment of Richard Pazdur as the Principal Deputy Commissioner for Drug Evaluation and Research (PDCR). This position makes him the agency’s top drug regulator, responsible for overseeing the review and approval of most prescription medications in the United States. Pazdur, a veteran of the FDA with a distinguished career in oncology drug growth, previously served as the director of the FDA’s Oncology center of Excellence.

Why is this Significant?

This appointment is particularly noteworthy given the increasing complexity of drug development and the FDA’s ongoing efforts to balance the need for faster access to innovative treatments with the imperative of ensuring patient safety and efficacy. Pazdur’s extensive experience in oncology, a field characterized by rapid advancements and frequently enough high-risk, high-reward therapies, positions him well to navigate these challenges. the PDCR role is crucial,as it directly influences which drugs reach the market and how quickly,impacting millions of patients.

Who is Richard Pazdur?

Richard Pazdur is a highly respected figure in the pharmaceutical and regulatory communities. He has spent over three decades at the FDA, becoming known for his rigorous approach to drug evaluation and his commitment to bringing effective cancer treatments to patients. Before leading the oncology Center of Excellence, he held various leadership positions within the FDA’s drug review divisions. He is a medical oncologist by training and has a deep understanding of the scientific and clinical aspects of drug development.

Timeline of Key Events

  • Early Career: Richard Pazdur begins his career as a medical oncologist.
  • 1990s: Joins the FDA, beginning a long tenure in drug evaluation.
  • 2005: Plays a key role in the accelerated approval of several important cancer drugs.
  • 2017: Appointed as the Director of the FDA’s Oncology Center of Excellence.
  • May 9, 2024: Named Principal Deputy Commissioner for drug Evaluation and Research.

Impact and Affected Parties

The appointment of richard Pazdur will have a broad impact on several key stakeholders